Study of KK2269 for adults with solid tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a solid tumor that has spread or can't be surgically removed (measurable by scans)
- Be in good enough health to be up and about (ECOG score 0 or 1)
- Have a life expectancy of at least 3 months
- Agree to use effective birth control if applicable
- For part 2: have a specific cancer type like stomach, esophagus, or lung cancer, and be able to receive a chemotherapy called docetaxel
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.